TrianglePembrolizumab (NCT06364917)
Pembrolizumab trial for Non Small Cell Lung Cancer (NCT06364917). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged eighteen to eighty-nine with stage-four non-small-cell lung cancer, PD-L1 below one percent, and detectable blood tumor DNA. First-line targetable drivers exclude participation.
The idea: random assignment compares pembrolizumab with nivolumab plus ipilimumab, each with chemotherapy. These antibodies block PD1 alone or PD1 and CTLA4 immune brakes. Chemotherapy pairs carboplatin with paclitaxel for squamous tumors or pemetrexed for nonsquamous tumors. Researchers measure blood tumor-DNA clearance after treatment.
This phase 2 study plans 24 patients. Aakash Desai leads at UAB, Birmingham, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.